A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

This study is looking for children and teenagers who are currently between 2 and 17 years old. They need to have chronic kidney disease, and their kidney function will be checked to make sure it falls within a certain range. This might be a good fit if your child is already taking stable medication for their kidney condition, such as certain blood pressure medicines, as these usually need to stay the same throughout the study.

There are also some reasons why a child might not be able to join. For example, children with type 1 or type 2 diabetes, or those who have had a condition called ketoacidosis recently, cannot take part. Also, if your child is currently on dialysis, has had a kidney transplant, or is planning to have a transplant during the study, they would not be eligible.

If your child joins the study, they will take either the study medicine (empagliflozin) or a dummy pill (placebo) once a day as a tablet for 6 months. After these first 6 months, everyone in the study will take empagliflozin once a day for another year. There's a 2 in 3 chance your child will get the active medicine from the start.

The study will last for about a year and a half in total. During this time, your child will need to visit the study clinic about 15 times for check-ups. There will also be at least 5 phone or video calls with the study team. At these visits, doctors will take blood and urine samples, and carefully monitor your child's overall health and any effects of the medicine.